Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$13 Mln
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$-178.50 Mln
EBITDA
$-190.49 Mln
Net Profit
$-216.81 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Imunon Inc (IMNN)
| -7.73 | -7.73 | -1.53 | -30.98 | -34.43 | -44.60 | -48.06 |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Imunon Inc (IMNN)
| 39.33 | -49.63 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Imunon, Inc., a clinical-stage biotechnology company, develops immunotherapies and next-generation vaccines. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II... clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey. Address: 997 Lenox Drive, Lawrenceville, NJ, United States, 08648 Read more
Executive Chairman
Mr. Michael H. Tardugno
Executive Chairman
Mr. Michael H. Tardugno
Headquarters
Lawrenceville, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Imunon Inc (IMNN) is $0.90 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Imunon Inc (IMNN) has given a return of -34.43% in the last 3 years.
Imunon Inc (IMNN) has a market capitalisation of $ 13 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Imunon Inc (IMNN) and enter the required number of quantities and click on buy to purchase the shares of Imunon Inc (IMNN).
Imunon, Inc., a clinical-stage biotechnology company, develops immunotherapies and next-generation vaccines. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey. Address: 997 Lenox Drive, Lawrenceville, NJ, United States, 08648
The CEO & director of Mr. Michael H. Tardugno. is Imunon Inc (IMNN), and CFO & Sr. VP is Mr. Michael H. Tardugno.
There is no promoter pledging in Imunon Inc (IMNN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Imunon Inc (IMNN) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Imunon Inc (IMNN) was $0 Mln.
$0.03
(
